Back to search
FDAFDA · Food and drugs·Recall number D-0324-2024

HydrALAZINE Hydrochloride Tablets, USP 10mg, packaged in 100-count (10x10 blister cards), Lot T04680, Rx only, Manufactured for Heritage Pharmaceuticals, Inc. Eatontown, NJ, Distributed by Major Pharmaceuticals Livonia MI. NDC 0904-6440-61

Published February 21, 2024 · Recall initiated: February 9, 2024

Summary

FDA records drug Class II recall D-0324-2024, published February 21, 2024 and initiated February 9, 2024. Recalling firm: The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories; Status: Terminated; Reported quantity: 8,198 units; Lot: Lot #: T04680, Exp. Date 6/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

an out of specification result obtained during routine stability testing for Impurities. There is a remote possibility that use of this product could cause a medically reversible or transient adverse health consequences.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories
Distributor
The product was distributed nationwide within the United States.
Lot
Lot #: T04680, Exp. Date 6/2024
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was HydrALAZINE Hydrochloride Tablets, USP 10mg, packaged in 100-count (10x10 blister cards), Lot T04680, Rx only, Manufactured for Heritage Pharmaceuticals, Inc. Eatontown, NJ, Distributed by Major Pharmaceuticals Livonia MI. NDC 0904-6440-61 recalled?

Yes. FDA published recall D-0324-2024 on February 21, 2024. Reported hazard: an out of specification result obtained during routine stability testing for Impurities. There is a remote possibility that use of this product could cause a medically reversible or transient adverse health consequences.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail